BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36518765)

  • 1. Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network.
    Li S; Li W; Ma T; Fu S; Gao X; Qin N; Wu Y; Zhang X; Wang J; Pan Y; Liu Z
    Front Immunol; 2022; 13():1024707. PubMed ID: 36518765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network.
    Li W; Fu S; Gao X; Lu Z; Jin R; Qin N; Zhang X; Wu Y; Li W; Wang J
    Front Immunol; 2023; 14():1141408. PubMed ID: 37056768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
    He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
    Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
    J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
    Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
    Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
    [No Abstract]   [Full Text] [Related]  

  • 6. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 7. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
    Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
    Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
    Gong J; Bao X; Wang T; Liu J; Peng W; Shi J; Wu F; Gu Y
    Oncoimmunology; 2022; 11(1):2028962. PubMed ID: 35096486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study.
    Jiang Y; Liang X; Han Z; Wang W; Xi S; Li T; Chen C; Yuan Q; Li N; Yu J; Xie Y; Xu Y; Zhou Z; Poultsides GA; Li G; Li R
    Lancet Digit Health; 2021 Jun; 3(6):e371-e382. PubMed ID: 34045003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 12. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Establishment of artificial neural network model for predicting lymph node metastasis in patients with stage Ⅱ-Ⅲ gastric cancer].
    Xue Z; Lu J; Lin J; Huang CM; Li P; Xie JW; Wang JB; Lin JX; Chen QY; Zheng CH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Apr; 25(4):327-335. PubMed ID: 35461201
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
    Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
    Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep learning with test-time augmentation for radial endobronchial ultrasound image differentiation: a multicentre verification study.
    Yu KL; Tseng YS; Yang HC; Liu CJ; Kuo PC; Lee MR; Huang CT; Kuo LC; Wang JY; Ho CC; Shih JY; Yu CJ
    BMJ Open Respir Res; 2023 Aug; 10(1):. PubMed ID: 37532473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome-Supervised Deep Learning on Pathologic Whole Slide Images for Survival Prediction of Immunotherapy in Patients with Non-Small Cell Lung Cancer.
    Li B; Yang L; Zhang H; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
    Mod Pathol; 2023 Aug; 36(8):100208. PubMed ID: 37149222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
    She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
    EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
    Prelaj A; Lo Russo G; Proto C; Signorelli D; Ferrara R; Galli G; De Toma A; Randon G; Pagani F; Trevisan B; Ganzinelli M; Zilembo N; Montrone M; Longo V; Pesola F; Pizzutilo P; Del Bene G; Varesano N; Galetta D; Torri V; Garassino MC; Di Maio M; Catino A
    Clin Lung Cancer; 2020 Sep; 21(5):e337-e348. PubMed ID: 32291212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peripheral Blood Inflammation Indicators as Predictive Indicators in 
Immunotherapy of Advanced Non-small Cell Lung Cancer].
    Xia J; Chen Y; Wen S; Du X; Shen B
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):632-645. PubMed ID: 34521188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.